Double maintains 2 strategies that include FOLD - Amicus Therapeutics, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LITB | -13.61% | $21.24M | -78.57% | 0.00% |
DFDV | -9.11% | $300.56M | +2,130.16% | 0.00% |
MCK | -8.40% | $88.11B | +20.93% | 0.40% |
NEUE | -6.87% | $61.24M | +29.92% | 0.00% |
HUSA | -5.85% | $19.66M | -19.53% | 0.00% |
K | -5.48% | $27.76B | +41.17% | 2.85% |
XOS | -5.32% | $26.93M | -52.42% | 0.00% |
BTCT | -4.22% | $25.56M | +61.14% | 0.00% |
FROG | -4.06% | $4.74B | +15.86% | 0.00% |
CPSH | -3.66% | $42.27M | +74.25% | 0.00% |
STG | -3.37% | $30.78M | -22.51% | 0.00% |
SRRK | -3.33% | $3.38B | +357.53% | 0.00% |
CNC | -3.30% | $16.81B | -49.40% | 0.00% |
MSIF | -2.99% | $769.47M | +36.17% | 7.61% |
AIFU | -2.94% | $6.79B | +102.19% | 0.00% |
CARV | -2.58% | $8.88M | +26.23% | 0.00% |
SAVA | -2.12% | $97.10M | -81.34% | 0.00% |
VSA | -2.09% | $8.67M | -19.04% | 0.00% |
LTM | -1.71% | $12.63B | -95.46% | 2.42% |
AQB | -1.24% | $2.96M | -53.35% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HNRG | 0.04% | $681.17M | +102.69% | 0.00% |
AGL | -0.09% | $989.35M | -60.10% | 0.00% |
CVS | -0.16% | $84.25B | +17.46% | 3.97% |
UPWK | 0.17% | $1.77B | +22.03% | 0.00% |
LRN | 0.19% | $5.99B | +100.06% | 0.00% |
ZCMD | 0.28% | $29.55M | -8.59% | 0.00% |
PRPO | -0.44% | $17.08M | +125.94% | 0.00% |
VSTA | -0.51% | $344.07M | +39.29% | 0.00% |
ASPS | -0.70% | $108.30M | -4.13% | 0.00% |
SCKT | -0.74% | $8.95M | +2.73% | 0.00% |
RLMD | 0.89% | $19.95M | -80.03% | 0.00% |
OXBR | 1.15% | $16.90M | +1.79% | 0.00% |
BMBL | 1.18% | $684.82M | -31.65% | 0.00% |
CCEC | 1.21% | $1.02B | +3.91% | 2.58% |
AQB | -1.24% | $2.96M | -53.35% | 0.00% |
DHT | 1.33% | $1.76B | -3.95% | 7.32% |
CBOE | 1.38% | $24.23B | +35.36% | 1.09% |
CYD | 1.57% | $890.68M | +164.07% | 3.83% |
PSQH | 1.60% | $98.82M | -36.55% | 0.00% |
FATBB | 1.63% | $49.01M | -5.66% | 10.18% |
Yahoo
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD)PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adult patients with late-onset Pompe disease (LOPD). "We are delighted that we will now be able to offer a compel
Finnhub
Amicus Therapeutics announced that Japan's Ministry of Health, Labour and Welfare has approved Pombiliti + Opfolda for the treatment of adult patients with late-onset Pompe disease . Pombiliti +...
Yahoo
Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the best biotech stocks to invest in now. On June 3, Amicus Therapeutics announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study in Muscle and Nerve. The analysis focused on the efficacy of Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) (cipa+mig) […]
SeekingAlpha
Amicus Therapeutics is growing steadily with Galafold and a promising Pompe therapy, targeting $1B revenue by 2028. See why FOLD stock is a buy.
Finnhub
Presenter SpeechShrunatra Mishra Hi, everyone. I am Shrunatra, research associate in the U.S. biotech team. And I'm joined today by Bradley Campbell, the President and CEO of Amicus Therapeutics....
Finnhub
PRINCETON - Amicus Therapeutics , announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat in adults with...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IMVT | 43.21% | $2.87B | -35.84% | 0.00% |
ROIV | 42.73% | $7.46B | +4.68% | 0.00% |
CLPT | 42.60% | $319.11M | +110.24% | 0.00% |
LLY | 41.36% | $738.55B | -13.23% | 0.72% |
MFA | 41.11% | $996.76M | -7.87% | 14.52% |
ATXS | 41.05% | $323.37M | -36.33% | 0.00% |
HROW | 40.83% | $1.12B | +41.49% | 0.00% |
OCSL | 40.74% | - | - | 13.60% |
BDX | 40.66% | $50.81B | -22.54% | 2.28% |
CPRX | 39.33% | $2.62B | +40.10% | 0.00% |
CWK | 39.22% | $2.70B | +11.27% | 0.00% |
CRH | 39.10% | $63.86B | +28.79% | 0.39% |
IRON | 39.07% | $1.84B | +19.67% | 0.00% |
ASH | 38.76% | $2.44B | -42.62% | 3.08% |
GEHC | 38.73% | $34.85B | -1.45% | 0.17% |
BIIB | 38.69% | $19.52B | -40.70% | 0.00% |
RITM | 38.59% | $6.19B | +9.67% | 8.53% |
TRTX | 38.34% | $645.25M | -5.83% | 11.90% |
DHR | 38.18% | $144.92B | -15.63% | 0.58% |
GRVY | 38.11% | $457.59M | -17.70% | 0.00% |
Current Value
$6.011 Year Return
Current Value
$6.011 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -35.12% | $164.54M | 0.85% |
TAIL | -31.79% | $99.63M | 0.59% |
BTAL | -18.93% | $296.22M | 1.43% |
XHLF | -10.34% | $1.73B | 0.03% |
FXY | -8.82% | $816.38M | 0.4% |
TFLO | -8.51% | $6.82B | 0.15% |
IBTF | -7.63% | $1.99B | 0.07% |
TPMN | -7.48% | $30.70M | 0.65% |
IVOL | -6.47% | $347.03M | 1.02% |
KCCA | -6.38% | $109.43M | 0.87% |
FXE | -5.70% | $568.94M | 0.4% |
ULST | -5.52% | $654.75M | 0.2% |
CORN | -5.40% | $44.67M | 0.2% |
FTSD | -5.15% | $231.81M | 0.25% |
XONE | -5.11% | $625.28M | 0.03% |
STOT | -4.92% | $254.07M | 0.45% |
TBLL | -3.66% | $2.13B | 0.08% |
UDN | -3.06% | $148.33M | 0.78% |
GBIL | -2.56% | $6.37B | 0.12% |
CLIP | -2.53% | $1.51B | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
USDU | 0.19% | $162.43M | 0.5% |
WEAT | 0.29% | $117.15M | 0.28% |
BWX | -0.57% | $1.53B | 0.35% |
SOYB | 0.59% | $26.67M | 0.22% |
IBTG | 0.62% | $1.92B | 0.07% |
PSQA | 0.63% | $35.44M | 0.2% |
CANE | 0.90% | $10.37M | 0.29% |
IBND | 1.05% | $384.31M | 0.5% |
IBMN | 1.34% | $447.08M | 0.18% |
SCHO | 1.39% | $11.03B | 0.03% |
SPTS | -1.46% | $5.80B | 0.03% |
GOVZ | -1.74% | $272.00M | 0.1% |
SHV | 1.89% | $20.64B | 0.15% |
AGGH | 2.17% | $324.95M | 0.29% |
UTWO | 2.38% | $379.52M | 0.15% |
CLIP | -2.53% | $1.51B | 0.07% |
GBIL | -2.56% | $6.37B | 0.12% |
BIL | 2.63% | $42.24B | 0.1356% |
UDN | -3.06% | $148.33M | 0.78% |
SHYM | 3.35% | $357.13M | 0.35% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBB | 50.87% | $5.26B | 0.45% |
XBI | 49.82% | $4.82B | 0.35% |
BBH | 49.52% | $330.62M | 0.35% |
PBE | 48.65% | $223.19M | 0.58% |
FBT | 48.36% | $1.01B | 0.54% |
PINK | 47.63% | $130.57M | 0.5% |
FHLC | 46.60% | $2.44B | 0.084% |
VHT | 46.00% | $15.35B | 0.09% |
IYH | 45.97% | $2.73B | 0.39% |
IHE | 45.70% | $550.45M | 0.39% |
XPH | 45.09% | $147.96M | 0.35% |
GNOM | 44.90% | $44.57M | 0.5% |
IXJ | 44.66% | $3.75B | 0.41% |
XLV | 43.87% | $34.28B | 0.09% |
PPH | 41.56% | $610.46M | 0.36% |
FXH | 41.13% | $903.07M | 0.62% |
QUS | 40.84% | $1.58B | 0.15% |
OUSA | 40.64% | $814.35M | 0.48% |
USMV | 40.52% | $23.82B | 0.15% |
PTH | 40.23% | $100.85M | 0.6% |